Comparative Pharmacology
Head-to-head clinical analysis: TRIPROLIDINE AND PSEUDOEPHEDRINE versus XYZAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIPROLIDINE AND PSEUDOEPHEDRINE versus XYZAL.
TRIPROLIDINE AND PSEUDOEPHEDRINE vs XYZAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Triprolidine is a first-generation antihistamine that antagonizes histamine H1 receptors, reducing histamine-mediated allergic symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and decreased nasal congestion.
Levocetirizine is a selective histamine H1-receptor antagonist; it inhibits the histamine-mediated responses in allergic conditions.
1 tablet (2.5 mg triprolidine/60 mg pseudoephedrine) orally every 4-6 hours; max 4 tablets/24 hours.
5 mg orally once daily in the evening.
None Documented
None Documented
Triprolidine: 2-4 hours (parent compound). Pseudoephedrine: 4-8 hours, prolonged in alkaline urine (up to 16-24 hours).
Terminal elimination half-life is approximately 7 hours in healthy adults; prolonged to 8–11 hours in elderly and in renal impairment.
Triprolidine: renal, 70% unchanged and metabolites. Pseudoephedrine: renal, 90% unchanged.
Approximately 84% of a dose is excreted renally as unchanged drug; 12% in feces via biliary elimination.
Category A/B
Category C
Antihistamine
Antihistamine